Welcome!

News Feed Item

Echo Therapeutics Announces Third Quarter 2012 Financial Results

Company to Host Conference Call Today, November 8, 2012 at 9:00 AM EST

PHILADELPHIA, Nov. 8, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced its financial results for the quarter ended September 30, 2012. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com.

(Logo:  http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

Recent Corporate Highlights

  • In preparation for its planned first quarter 2013 ISO audit, Echo made substantial advances towards finalizing its quality management systems.  ISO certification is a key step towards achieving compliance with European regulatory requirements.
  • Echo initiated the process of conducting clinical studies at investigational sites in Europe and the U.S. to support CE Mark and other commercialization efforts.
  • Echo hired key development, product, and clinical personnel to prepare for and accelerate its plans for Symphony's European and U.S. regulatory clearance and commercialization.

"We had a very productive third quarter, with significant progress made towards the Company's clinical, development and regulatory objectives needed to commercialize our Symphony system," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics.  "As we look toward 2013, we remain focused on obtaining European clearance of Symphony and its commercial launch, as well as initiating our pivotal studies to support PMA submission in the U.S."

Third Quarter 2012 Financial Results
Echo's net loss for the third quarter of 2012 was $4.3 million, or $0.11 per share, compared to $1.5 million, or $0.04 per share, for the third quarter of 2011.  The operating loss for the third quarter of 2012 was $3.6 million compared to $2.3 million for the third quarter of 2011.  Research and development expenses were $2.1 million for the third quarter of 2012 compared to $0.7 million for the third quarter of 2011.  The increase in research and development expenses was primarily related to increased development, regulatory and clinical expenses, as well as manufacturing preparation costs.  General and administration expenses were flat from period to period and attributable to personnel and facility costs, as well as legal and other public company expenses. 

Echo reported a cash balance of approximately $1.4 million as of September 30, 2012.  In August of 2012, Echo's financial position was augmented by a $20 million credit facility with Platinum-Montaur Life Sciences, LLC.  To date, Echo has received $3 million in cash proceeds from that facility. 

Conference Call
Management will host a conference call today starting at 9:00 AM EST.  To listen in and/or participate in the call, please dial 877.317.6789 and reference the conference number 10020170.  The archived audiocast will be available for fourteen days following the call by visiting the Events section of Echo's website at www.echotx.com.

About Echo Therapeutics
Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system.  Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care.  Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting.  Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony tCGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio                                         
Director, Investor Relations and Corporate Communications
(215) 717-4104                                                 

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx

 


Echo Therapeutics, Inc

Condensed Consolidated Balance Sheets

 



September 30,

2012


December 31,

2011


ASSETS





Current Assets:





Cash and cash equivalents

$      1,395,840


$      8,995,571


Current portion of deferred financing costs

1,068,462


-


Prepaid expenses, cash restricted pursuant to letters of credit

 and other current assets

482,172


567,940


Total current assets

2,946,474


9,563,511


Net property and equipment (including assets under capitalized leases)

1,205,845


317,731


Other Assets:





Intangible assets, net of accumulated amortization

9,625,000


9,625,000


Deferred financing costs

3,791,329


-


Other assets

10,566


20,565


Total other assets

13,426,895


9,645,565


Total assets

$    17,579,214


$    19,526,807







LIABILITIES AND STOCKHOLDERS' EQUITY





Current Liabilities:





Accounts payable

$      1,029,488


$         365,298


Deferred revenue from licensing arrangements

92,794


123,708


Derivative warrant liability

6,772,536


1,035,337


Accrued expenses and other liabilities

1,315,930


968,120


Total current liabilities

9,210,748


2,492,463


Note payable, net of discount and capital lease obligation, net of current portion

7,573


65,755


Total liabilities

9,218,321


2,558,218


Commitments





Stockholders' Equity:





Convertible preferred stock, Series C & D

30,160


30,160


Common stock

399,116


385,442


Additional paid-in capital

99,906,833


98,116,327


Common stock subscribed for but not paid for or issued

-


6,667


Accumulated deficit

(91,975,216)


(81,570,007)


Total stockholders' equity

8,360,893


16,968,589


Total liabilities and stockholders' equity

$    17,579,214


$    19,526,807



 

 

 

Condensed Consolidated Statements of Operations

 


Three Months Ended

September 30,


Nine Months Ended

September 30,


2012


2011


2012


2011

Licensing revenue

$           30,927


$          (44,360)


$           92,781


$         198,550

Other revenue

-


-


-


145,152

Total revenues

30,927


(44,360)


92,781


343,702









Operating Expenses:








Research and development

2,139,465


695,019


5,731,417


2,557,118

Selling, general and administrative

1,508,069


1,527,317


4,702,325


3,427,582

Total operating expenses

3,647,534


2,222,336


10,433,742


5,984,700

Loss from operations

(3,616,607)


(2,266,696)


(10,340,961)


(5,640,998)









Other Income (Expense):








Interest income (expense), net

(88,488)


196


(84,257)


(9,869)

Debt financing costs

(160,000)


-


(160,000)


-

Loss on extinguishment of debt/payables

-


-


-


(1,514)

Gain (loss) on disposals of assets

-


-


(21,272)


834

Gain (loss) on revaluation of derivative warrant liability

(400,000)


893,229


201,281


(2,258,679)

Other income (expense), net

(648,488)


893,425


(64,248)


(2,269,228)

Net loss

(4,265,095)


(1,373,271)


(10,405,209)


(7,910,226)

Deemed dividend on repricing of warrants

-


(87,500)


-


(87,500)

Accretion of dividends on Convertible Perpetual
Redeemable Preferred Stock

-


(49,519)


-


(142,761)

Deemed dividend on beneficial conversion feature of
Series D Convertible Preferred Stock

-


-


-


(1,975,211)

Net loss applicable to common shareholders

$     (4,265,095)


$     (1,510,290)


$   (10,405,209)


$   (10,115,698)

Net loss per common share, basic and diluted

$              (0.11)


$              (0.04)


$              (0.27)


$              (0.30)

Basic and diluted weighted average common shares     outstanding

39,858,876


34,295,425


39,256,372


33,620,751













 

 

SOURCE Echo Therapeutics, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, provided a fun and simple way to introduce Machine Leaning to anyone and everyone. He solved a machine learning problem and demonstrated an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intelligence and B...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
"IBM is really all in on blockchain. We take a look at sort of the history of blockchain ledger technologies. It started out with bitcoin, Ethereum, and IBM evaluated these particular blockchain technologies and found they were anonymous and permissionless and that many companies were looking for permissioned blockchain," stated René Bostic, Technical VP of the IBM Cloud Unit in North America, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventi...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
The need for greater agility and scalability necessitated the digital transformation in the form of following equation: monolithic to microservices to serverless architecture (FaaS). To keep up with the cut-throat competition, the organisations need to update their technology stack to make software development their differentiating factor. Thus microservices architecture emerged as a potential method to provide development teams with greater flexibility and other advantages, such as the abili...
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.
Leading companies, from the Global Fortune 500 to the smallest companies, are adopting hybrid cloud as the path to business advantage. Hybrid cloud depends on cloud services and on-premises infrastructure working in unison. Successful implementations require new levels of data mobility, enabled by an automated and seamless flow across on-premises and cloud resources. In his general session at 21st Cloud Expo, Greg Tevis, an IBM Storage Software Technical Strategist and Customer Solution Architec...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...